glp 1 medication shortage Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s GLP-1 Medications No Longer in

The CV benefits of the SGLT2 inhibitor on HF and CV death (primarily driven by HF) are observed with months and most likely are hemodynamically driven (simultaneous reduction in preload and afterload), while those of GLP-1s on MACE take 12 to 16 months to be seen and most likely are related to the drugs antiatherogenic effects

WHAT'S CHANGING UHC Coverage Outlook for 2026 Good news: UHC and OptumRx are maintaining Wegovy on 2026 formularies for plans that currently cover obesity medications

But even with that long list of upsides, theres still one pesky side effect many struggle with while taking a GLP-1: muscle loss

It's not in the market yet but is expected to be soon...patiently waiting to see how it compares to the cost of other newly launched generics (especially as a GLP-1 RA)